Brief: Candel Therapeutics Inc - Announces Encouraging Interim Data From CAN-3110 Trial
14/10/2025 13:17
Oct 14 (Reuters) - Candel Therapeutics Inc CADL.O: CANDEL THERAPEUTICS INC - ANNOUNCES ENCOURAGING INTERIM DATA FROM CAN-3110 TRIAL CANDEL THERAPEUTICS INC - UPDATED MEDIAN OS OF 11.8 MONTHS FOR ARM A, 12.0 MONTHS FOR ARM B Source text: ID:nGNX1vqDPC Further company coverage: CADL.O
Recent news on Candel Therapeutics
See all newsBrief: Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Candel Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Candel Therapeutics Reports Second Quarter 2026 Financial Results And Recent Corporate Highlights
Candel Therapeutics Inc expected to post a loss of 24 cents a share - Earnings Preview
Brief: Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)